

# The 18th JFCR-ISCC

## New Antitumor Agents under Development in the US, Europe and Japan



**2013**

**December 4, (Wed)**  
13:00 - 17:00

**December 5, (Thu)**  
9:00 - 17:30

**Miraikan**

National Museum of  
Emerging Science and Innovation  
2-3-6, Aomi, Koto-ku, Tokyo, Japan

Contact:  
Cancer Chemotherapy Center,  
Japanese Foundation for Cancer Research  
jfc-r-iscc@ml.jfcr.or.jp

<http://iscc.umin.jp/>

**Dec. 4**

### New Approaches to Immunotherapy

13:10 -

**Hiroyoshi Nishikawa** *Osaka University*  
Regulatory T cells: Friends or foes for cancer?

**Ronald Peck** *BMS*  
Anti CTLA-4 antibody and other immuno-oncology drugs

### New Technology for Targeted Therapies

14:30 -

**Mark J. Ratain** *University of Chicago*  
Understanding the inconsistencies between  
cancer pharmacogenomic studies

**Seiichi Mori** *Genome Center, JFCR*  
Functional genomics identifies five distinct molecular  
subtypes with clinical relevance and pathways for  
growth control in epithelial ovarian cancer

**Yasuhiro Matsumura** *National Cancer Center,  
Hospital East*  
Nanomicelles DDS technology combined with active targeting

### Poster Session

16:00 -

**Dec. 5**

### Circulating Tumor Cells and Biomarkers

9:00 -

**Stefan Sleijfer** *Erasmus MC, Cancer Institute*  
The role of circulating tumor cell (CTCs) enumeration and  
characterization in early clinical drug development

**Aditya Bardia** *MGH Cancer Center*  
Molecular evaluation of circulating tumor cells for drug  
development in metastatic breast cancer

**Johann de Bono** *ICRUK*  
Studying circulating biomarkers in early clinical trials

### Poster Discussion Session

11:00 -

### Luncheon Seminar

12:00 -

**Wenbin Ying & Kenjiro Minomi**

*Nitto Denko Technical Corp*  
Delivery of anticancer drug in a polymer micelle with  
a unique drug release property

### Special Lecture

13:00 -

**Frank McCormick** *UCSF*  
Treating cancer based on the ras pathway

### Promising Molecular Targets for Cancer Therapy

14:30 -

**Keith T. Flaherty** *MGH*  
MEK inhibition in BRAF mutant melanoma and beyond

**Yves G. Pommier** *NCI*  
PARP inhibitors and trapping of PARP-DNA complexes

### New Drugs under Clinical Trials

15:40 -

**Chiang J. Li** *Boston Biomedical, Inc.*  
Targeting cancer stem cells: Development of BBI608 and  
BBI503

**Andrew Allen** *Clovis Oncology*  
CO-1686: a novel, mutant-selective EGFR inhibitor with  
clinical activity against T790M mutations and sparing of  
wild-type EGFR

**Anthony W. Tolcher** *START*  
CDK4/6 inhibitor